Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2561)	1/13/2001 5:43:21 PM
From: Thomas M.	Respond to of 52153

<<< "About five years ago, Warner-Lambert was sort of a second-rate company," he says. "It was a lackluster drug company and it was in the penalty box at the FDA," because of costly manufacturing deficiencies. Yet Wichman was high on a couple of products in the drug pipeline "that could really change the company" if they were approved. "I got the guys together and said, 'At some point, we're going to want to own this stock," " says Wichman, who began his career in 1969 at the old Shearson Hammill. Some time after that Warner-Lambert got an insequential product approved by the FDA, one that the Wall Street analysts virtually ignored because it had little financial importance in the short term. To Wichman, however, it was clear evidence that the company was off the FDA's blacklist. >>> I did not know the FDA blacklists companies. Tom